Deferoxamine (DFO)

DRUG4 trials

Conditions

Cardiac Iron OverloadHemolytic AnemiaIron OverloadLeptomeningeal MetastasesPateints of β-thalassemia Major With Iron OverloadSickle Cell DiseaseTransfusion-dependent β-thalassemia Patients

Phase 1

A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis

RecruitingNCT05184816

Memorial Sloan Kettering Cancer CenterLeptomeningeal Metastases

Start: 2021-12-22End: 2027-12-01Target: 32Updated: 2026-07-14

Phase 2

Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients

CompletedNCT00110617

Novartis PharmaceuticalsHemolytic Anemia, Iron Overload, Sickle Cell Disease

Start: 2005-05-31End: 2008-04-30Updated: 2011-05-26

Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron Overload

TerminatedNCT01459718

Novartis PharmaceuticalsCardiac Iron Overload, Transfusion-dependent β-thalassemia Patients

Start: 2011-01-31End: 2014-06-30Updated: 2019-10-23

Unknown Phase

Comparison of Deferasirox and Desferoxamine in Patients of β-Thalassemia Major With Iron Overload

CompletedNCT06468423

RESnTEC, Institute of ResearchPateints of β-thalassemia Major With Iron Overload

Start: 2023-01-01End: 2023-09-30Updated: 2024-06-21

Related Papers

Intrathecal deferoxamine in patients with leptomeningeal metastases: Phase 1a analysis.

Journal of Clinical Oncology2025-05-28

A phase Ia/Ib study of intrathecal deferoxamine in patients with leptomeningeal metastases.